No new efficacy or safety numbers were disclosed. Still, AAVantgarde Bio will present updated Phase 1/2 LUCE-1 data for AAVB-081, its dual AAV gene therapy targeting MYO7A-related Usher syndrome type 1B retinitis pigmentosa, at EURETINA 2025 in Paris. The oral readout follows earlier signals previewed at FLORetina in December 2024 and ARVO in May 2025 and will cover the multicenter, subretinal, dose-escalation design evaluating three dose levels (NCT06591793).
The core news is a directional progression milestone: a first-in-human program for a large-gene retinal disorder advancing steadily through dose escalation with a planned detailed update on safety, tolerability, and preliminary efficacy. AAVantgarde is also positioning the wider platform around dual-vector delivery by presenting at Ophthalmology Futures Forum and the EURetina Innovation Spotlight, signaling an interest in partnerships and capital alignment as the MYO7A program and a companion Stargardt program (AAVB-039) move forward.
Strategically, this is an execution bet on dual-vector gene therapy for oversized genes that do not fit in a single AAV cassette. The previous wave of MYO7A approaches leaned on lentiviral delivery and struggled to reach late development; the field has since shifted toward dual AAV reconstitution in photoreceptors and RPE. Suppose LUCE-1 shows a coherent safety profile and even modest, consistent functional gains. In that case, AAVantgarde can carve out first-mover advantage in Usher 1B while building a platform halo for other large-gene indications. The choice of subretinal delivery ensures that dosing is tightly localized and operationally controlled. Still, it concentrates risk around surgery, perioperative management, and inflammation, and it sets a high bar for standardization across sites.
For sites, the implications are straightforward and resource-intensive: surgery-capable retina centers, experienced vitreoretinal surgeons, OR scheduling, consistent bleb creation, and disciplined perioperative immunosuppression protocols. Centralized imaging, microperimetry, full-field stimulus testing, and OCT-based structural assessments will demand high-fidelity data capture and robust calibration across centers. Sponsors and CROs will need to manage vector-to-vector ratio control at the point of manufacture and administration, train for co-administration workflows, and maintain real-time oversight of inflammation events. Recruitment relies on rapid genetic confirmation and referral networks in a small, geographically dispersed population, with limited scope for decentralization due to the surgical intervention. Regulators are likely to emphasize functional endpoints beyond BCVA, including microperimetry and mobility, and will scrutinize dose-response, interocular consistency, and durability, given the challenges of redosing AAV.
What matters next are the specifics AAVantgarde brings to the stage in Paris: the magnitude and consistency of sensitivity gains on microperimetry or FST, any improvements in mobility or vision-guided navigation, and a straightforward safety narrative on intraocular inflammation, chorioretinal atrophy, and off-target effects. Clarity on dose-escalation outcomes, cohort expansion plans, and whether the program is trending toward RMAT or PRIME requests would signal regulatory confidence. Operationally, watch for how the company addresses dual-vector CMC, including vector ratio specifications, potency assays, and comparability strategy as it scales manufacturing. Trial design choices in the next phase—such as sham or delayed-treatment controls, unilateral versus bilateral dosing, and endpoint selection aligned with evolving FDA and EMA expectations—will determine both the speed and likelihood of approval. Suppose the EURETINA update reveals a credible safety window with early functional benefits. In that case, the pressure will shift to establishing a specialized surgical site network and securing supply chain readiness for a two-vector product, ahead of pivotal planning.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
